Fewer than one in 10 patients who could benefit from obesity jabs like Wegovy can access them, warns the World Health Organization as it releases its initial advice on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to this class of drugs.
Based on projections, over two billion could be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a chronic disease that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the treatments that can assist patients in reducing substantial weight, says the body.
GLP-1 Therapy Shortage
Despite the present most favorable scenario, the production of these medications might only reach around 100 million people – less than 10% of those who need them, per the WHO.
The recommendation urges nations and manufacturers to increase access, via approaches such as licensing agreements.
The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is set to lapse in multiple nations in 2026.
How Obesity Drugs Function
These medications mimick a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.
Evidence suggests users may regain a significant portion after a year of discontinuing the drug, because their usual food cravings resume.
To be above a healthy weight raises your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns people in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
